“The present problem has uncovered some structural weaknesses while in the EU’s medicines supply chain as well as a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides reported. She advisable that supply chain issues be tackled in an EU pharmaceutical method envisi